title: Lenalidomide-based combined therapy induced alterations in serum proteins of multiple myeloma patient: a follow-up case report and overview of the literature.
abstract: OBJECTIVE
  Multiple myeloma (MM) is a malignant neoplasm of plasma cells (PC) derived from the bone marrow (BM) origin. The present case report was aimed to monitor the efficiency of lenalidomide-based combined therapy (LBCT) induced alterations in serum proteins of 42-year-old female MM patient. Besides, in the context of case report we also present an overview of the literature describing LBCT.
  
  
  METHODS
  Serum protein electrophoresis (SPEP) was performed in three visits (V(1)-V(3)) to monitor the disease status of the patient and her treatment response to LBCT. Level of monoclonal protein (M-protein) was measured through cellulose acetate zone electrophoresis and quantified by densitometer in follow-up investigations after therapy intervals.
  
  
  RESULTS
  A significant reduction of M-protein in γ-globulin region was observed (P < 0.007) after receiving LBCT. However, the condition depicted hyper γ-globulinemia. β-globulin (P < 0.002) and α(2)-globulin(P < 0.047) was suppressed from the initial visit and subsequent follow-up also indicated the status of hypoglobulinaemia. Although, serum albumin level was found to be increased after therapy (P < 0.016), hypoalbuminaemia was also noticed before and after LBCT.
  
  
  CONCLUSIONS
  On the basis of this case report and pertinent literature, we conclude that LBCT is more efficient in the treatment of MM and has significant role in serum protein alterations especially in the reduction of M-protein in the MM patients.
authors.affiliation: Clinical Cytogenetic Laboratory, Department of Research, Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal - 462 001 Madhya Pradesh, India. sengenetics@gmail.com
authors.forename: C S
authors.initials: CS
authors.lastname: Senthilkumar
authors.forename: N
authors.initials: N
authors.lastname: Ganesh
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001798:Blood Proteins / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D001798:Blood Proteins; D013792:Thalidomide; D000077269:Lenalidomide